Eclipsebio logo
Contact Us

Analysis of the combined effect of rs699 and rs5051 on angiotensinogen expression and hypertension

  • Published April 8, 2023
  • by Eclipsebio

Share

Intro text lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Related articles

Press Releases

01
26
26

Eclipsebio Acquires Terrain Bio to Expand Its End-to-End AI Platform for the Design, Manufacturing, and Validation of RNA Therapeutics

Originally posted on Business Wire SAN DIEGO, January 26, 2026 — Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in sequencing-based analytics for RNA therapeutics, today announced the acquisition of Terrain Bio, a techbio company specializing in AI/ML RNA design and manufacturing analytics. The acquisition accelerates Eclipsebio’s strategy to deliver an integrated, data-first platform to support RNA […]

read more
Blue spiraling RNA

eBlogs

01
15
26

Achieving regulatory requirements by measuring IVT RNA integrity 

As RNA therapeutics and regulatory requirements advance, validation methods for IVT RNA integrity are advancing as well.

read more

eBlogs

12
10
25

RNA advancements and innovations: A 2025 review

In this latest eBlog, the Eclipsebio team looks back to some of the year's breakthroughs and ahead to future innovations.

read more
Happy Thanksgiving from Eclipsebio

eBlogs

11
24
25

State of Eclipsebio – 2025

In this Thanksgiving-themed blog, our CEO reflects on the past year at Eclipsebio and looks forward to 2026.

read more